Iovance Biotherapeutics Inc (NASDAQ: IOVA) kicked off on Friday, down -7.69% from the previous trading day, before settling in for the closing price of $2.73. Over the past 52 weeks, IOVA has traded in a range of $1.64-$8.15.
Over the past five-year period, the growth rate of yearbook sales for the company of the Healthcare sector was 4.17%. While this was happening, its average annual earnings per share was recorded 15.83%. With a float of $338.65 million, this company’s outstanding shares have now reached $385.46 million.
Iovance Biotherapeutics Inc (IOVA) Breakdown of a Key Holders of the stock
Our next focus will be how large-scale investors are participating in this stock of the Biotechnology Industry. The insider ownership of Iovance Biotherapeutics Inc is 14.69%, while institutional ownership is 47.04%. The most recent insider transaction that took place on Jun 05 ’25, was worth 55,200. In this transaction Chief Commercial Officer of this company bought 30,000 shares at a rate of $1.84, taking the stock ownership to the 30,000 shares. Before that another transaction happened on May 23 ’25, when Company’s Chief Regulatory Officer bought 5,600 for $1.74, making the entire transaction worth $9,743. This insider now owns 206,852 shares in total.
Iovance Biotherapeutics Inc (IOVA) Recent Fiscal highlights
In the latest quarterly report, which was put into the public domain on 12/31/2024, the organization reported -0.26 earnings per share (EPS), higher than consensus estimate (set at -0.27) by 0.01. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.15 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 15.83% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 45.62% during the next five years compared to 4.17% growth over the previous five years of trading.
Iovance Biotherapeutics Inc (NASDAQ: IOVA) Trading Performance Indicators
Take a look at Iovance Biotherapeutics Inc’s (IOVA) current performance indicators. Last quarter, stock had a quick ratio of 3.00. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 3.99.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.20, a number that is poised to hit -0.17 in the next quarter and is forecasted to reach -0.59 in one year’s time.
Technical Analysis of Iovance Biotherapeutics Inc (IOVA)
As of the previous 9 days, the stock’s Stochastic %D was 44.78%.
During the past 100 days, Iovance Biotherapeutics Inc’s (IOVA) raw stochastic average was set at 61.79%, which indicates a significant increase from 48.35% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 0.19 in the past 14 days, which was higher than the 0.17 volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $2.35, while its 200-day Moving Average is $2.44. Nevertheless, the first resistance level for the watch stands at $2.73 in the near term. At $2.93, the stock is likely to face the second major resistance level. The third major resistance level sits at $3.05. If the price goes on to break the first support level at $2.41, it is likely to go to the next support level at $2.29. Now, if the price goes above the second support level, the third support stands at $2.09.
Iovance Biotherapeutics Inc (NASDAQ: IOVA) Key Stats
The company with the Market Capitalisation of 1.00 billion has total of 396,968K Shares Outstanding. Its annual sales at the moment are 164,070 K in contrast with the sum of -372,180 K annual income. Company’s last quarter sales were recorded 67,460 K and last quarter income was -91,250 K.
